JP2022538602A - Akr1c3阻害剤およびその医学的使用 - Google Patents
Akr1c3阻害剤およびその医学的使用 Download PDFInfo
- Publication number
- JP2022538602A JP2022538602A JP2021577319A JP2021577319A JP2022538602A JP 2022538602 A JP2022538602 A JP 2022538602A JP 2021577319 A JP2021577319 A JP 2021577319A JP 2021577319 A JP2021577319 A JP 2021577319A JP 2022538602 A JP2022538602 A JP 2022538602A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- membered
- cancer
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010065942 Prostaglandin-F synthase Proteins 0.000 title claims abstract description 12
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 title claims abstract description 5
- 239000003112 inhibitor Substances 0.000 title abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 192
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- 239000012453 solvate Substances 0.000 claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 157
- 201000011510 cancer Diseases 0.000 claims description 71
- -1 isocyano, hydroxyl Chemical group 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 54
- 239000003814 drug Substances 0.000 claims description 47
- 238000002512 chemotherapy Methods 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000000623 heterocyclic group Chemical class 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 206010060862 Prostate cancer Diseases 0.000 claims description 31
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 31
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 31
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 238000001959 radiotherapy Methods 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 238000009169 immunotherapy Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 13
- 201000009273 Endometriosis Diseases 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 125000004437 phosphorous atom Chemical group 0.000 claims description 13
- 125000005638 hydrazono group Chemical group 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 9
- 229960000975 daunorubicin Drugs 0.000 claims description 9
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 7
- 229960000684 cytarabine Drugs 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
- 206010058019 Cancer Pain Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010039792 Seborrhoea Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 4
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims description 4
- 201000010260 leiomyoma Diseases 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 230000001235 sensitizing effect Effects 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 4
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 201000007954 uterine fibroid Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 150000001447 alkali salts Chemical group 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 3
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 claims description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims description 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical group CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000004360 trifluorophenyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 230000035945 sensitivity Effects 0.000 claims 3
- 150000008043 acidic salts Chemical class 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 175
- 238000006243 chemical reaction Methods 0.000 description 114
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 77
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 56
- 230000015572 biosynthetic process Effects 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 238000004128 high performance liquid chromatography Methods 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 26
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 239000003098 androgen Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000010189 synthetic method Methods 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 18
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 16
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 16
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 229960003387 progesterone Drugs 0.000 description 15
- 239000000186 progesterone Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229940045799 anthracyclines and related substance Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 229940011871 estrogen Drugs 0.000 description 10
- 239000000262 estrogen Substances 0.000 description 10
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 9
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 9
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 201000010066 hyperandrogenism Diseases 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108090000604 Hydrolases Proteins 0.000 description 7
- 102000004157 Hydrolases Human genes 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 229960004671 enzalutamide Drugs 0.000 description 7
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 6
- 229960005471 androstenedione Drugs 0.000 description 6
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 description 5
- 108010016731 PPAR gamma Proteins 0.000 description 5
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 229940030486 androgens Drugs 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 229960003712 propranolol Drugs 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- PXGPLTODNUVGFL-ZWAKLXPCSA-N 11-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-ZWAKLXPCSA-N 0.000 description 4
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 206010020112 Hirsutism Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 150000003536 tetrazoles Chemical class 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- VNDWQCSOSCCWIP-UHFFFAOYSA-N 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Chemical compound C1=2C=CNC(=O)C=2C2=CC(F)=CC=C2C2=C1NC(C(C)(C)C)=N2 VNDWQCSOSCCWIP-UHFFFAOYSA-N 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 201000002595 endometriosis of ovary Diseases 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 208000030747 ovarian endometriosis Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000008039 phosphoramides Chemical class 0.000 description 3
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- YQYGGOPUTPQHAY-KIQLFZLRSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccccc1)NC(=O)C(CCCCNN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)[C@H](C)O)C(C)C)[C@H](C)O YQYGGOPUTPQHAY-KIQLFZLRSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- KRGXWTOLFOPIKV-UHFFFAOYSA-N 3-(methylamino)propan-1-ol Chemical compound CNCCCO KRGXWTOLFOPIKV-UHFFFAOYSA-N 0.000 description 2
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 101150028310 AKR1C3 gene Proteins 0.000 description 2
- 102100029361 Aromatase Human genes 0.000 description 2
- NWGZZGNICQFUHV-OAHLLOKOSA-N C[C@@H](OP(=O)(N1CC1)N1CC1)C1=CC(OC2=CC(=CC=C2)C(=O)N(C)C)=C(C=C1)[N+]([O-])=O Chemical compound C[C@@H](OP(=O)(N1CC1)N1CC1)C1=CC(OC2=CC(=CC=C2)C(=O)N(C)C)=C(C=C1)[N+]([O-])=O NWGZZGNICQFUHV-OAHLLOKOSA-N 0.000 description 2
- 102100029801 Calcium-transporting ATPase type 2C member 1 Human genes 0.000 description 2
- 108050001979 Calcium-transporting ATPase type 2C member 1 Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000012624 DNA alkylating agent Substances 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 2
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241000187081 Streptomyces peucetius Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000002253 acid Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- UQUPIHHYKUEXQD-UHFFFAOYSA-N n,n′-dimethyl-1,3-propanediamine Chemical compound CNCCCNC UQUPIHHYKUEXQD-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008789 oxidative DNA damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- YZIIKMBFHLJAFT-ICSRJNTNSA-N trans-3,4-Dihydro-3,4-dihydroxy-7,12-dimethylbenz[a]anthracene Chemical compound C1=C[C@H](O)[C@@H](O)C2=CC=C3C(C)=C(C=CC=C4)C4=C(C)C3=C21 YZIIKMBFHLJAFT-ICSRJNTNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000023747 urothelial carcinoma Diseases 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 1
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 1
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- LORRLQMLLQLPSJ-UHFFFAOYSA-N 1,3,5-trithiane Chemical compound C1SCSCS1 LORRLQMLLQLPSJ-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 108010082514 17-Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- 102000004026 17-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 description 1
- 101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- QQFWMPUXPLBWTG-UHFFFAOYSA-N 2,4,6-trifluorophenol Chemical compound OC1=C(F)C=C(F)C=C1F QQFWMPUXPLBWTG-UHFFFAOYSA-N 0.000 description 1
- BICHBFCGCJNCAT-UHFFFAOYSA-N 2,4-difluorobenzenethiol Chemical compound FC1=CC=C(S)C(F)=C1 BICHBFCGCJNCAT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NRZNTGUFHSJBTD-HKOYGPOVSA-N 2-[2-(2-methoxyethoxy)ethoxy]ethyl (e)-2-cyano-3-(6-piperidin-1-ylnaphthalen-2-yl)prop-2-enoate Chemical compound C1=CC2=CC(/C=C(C(=O)OCCOCCOCCOC)\C#N)=CC=C2C=C1N1CCCCC1 NRZNTGUFHSJBTD-HKOYGPOVSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 108010060191 3(17)-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- TULKODADVOEVTR-UHFFFAOYSA-N 3-hydroxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(O)=C1 TULKODADVOEVTR-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- RAJWOBJTTGJROA-WZNAKSSCSA-N 5alpha-androstane-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 RAJWOBJTTGJROA-WZNAKSSCSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 102100026446 Aldo-keto reductase family 1 member C1 Human genes 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 102100035619 DNA-(apurinic or apyrimidinic site) lyase Human genes 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
- 101000718028 Homo sapiens Aldo-keto reductase family 1 member C1 Proteins 0.000 description 1
- 101000919395 Homo sapiens Aromatase Proteins 0.000 description 1
- 101001137256 Homo sapiens DNA-(apurinic or apyrimidinic site) lyase Proteins 0.000 description 1
- 101000928746 Homo sapiens Dehydrogenase/reductase SDR family member 9 Proteins 0.000 description 1
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 1
- 101000579300 Homo sapiens Prostaglandin F2-alpha receptor Proteins 0.000 description 1
- 101000896517 Homo sapiens Steroid 17-alpha-hydroxylase/17,20 lyase Proteins 0.000 description 1
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 101100042880 Mus musculus Snai3 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100028248 Prostaglandin F2-alpha receptor Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 150000001537 azepanes Chemical class 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 101150113535 chek1 gene Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- CYKLGTUKGYURDP-UHFFFAOYSA-L copper;hydrogen sulfate;hydroxide Chemical compound O.[Cu+2].[O-]S([O-])(=O)=O CYKLGTUKGYURDP-UHFFFAOYSA-L 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LJXTYJXBORAIHX-UHFFFAOYSA-N diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1 LJXTYJXBORAIHX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical class CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- NFMHSPWHNQRFNR-UHFFFAOYSA-N hyponitrous acid Chemical compound ON=NO NFMHSPWHNQRFNR-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BIFDXOOJPDHKJH-UHFFFAOYSA-N piperidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCCC1 BIFDXOOJPDHKJH-UHFFFAOYSA-N 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229940077150 progesterone and estrogen Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 150000003176 prostaglandin J2 derivatives Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 230000000365 steroidogenetic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003551 thiepines Chemical class 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
- C07C333/18—Esters of dithiocarbamic acids
- C07C333/20—Esters of dithiocarbamic acids having nitrogen atoms of dithiocarbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/18—Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part
- C07C33/20—Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65848—Cyclic amide derivatives of acids of phosphorus, in which two nitrogen atoms belong to the ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
R1およびR2が、それぞれ独立して、水素、重水素、アリールまたはZ-置換アリール、ヘテロアリールまたはZ-置換ヘテロアリール、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、またはC3-C8シクロアルキルまたはZ-置換シクロアルキルであり;
R3が水素、ハロゲン、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR3が-CONR6R7、-SO2NR6R7、-SO2R6、-OCO-R6、-OCOO-R6、-COOR6、-NR6COR7、-NR6SO2R7、または-NR6CONR6R7であって、R6およびR7は、Nと共に、4~8員Z-置換複素環を形成するか形成せず;
R6およびR7が、それぞれ独立して、水素、シアノまたはイソシアノ、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシ、またはR6およびR7は、それらが結合している原子と共に、3~7員複素環ラジカルまたはZ-置換3~7員複素環ラジカルを形成し;
aが、0、1、2または3であり;
Xが、CまたはNであり;
上記化学式において、R3は、ベンゼン環またはピリジン環の異なる原子上に位置していてもよい。例えば、aが0である場合、すなわちベンゼン環またはピリジン環上に水素が存在する場合、R3基がなくてもよく;aが1である場合、すなわちベンゼン環またはピリジン環上の残りの2個(ピリジン環の場合)または3個(ベンゼン環の場合)の水素原子が1個のR3基で置換されている場合、R3基は1個でもよく;aが2である場合、すなわちベンゼン環またはピリジン環上の残りの2個(ピリジン環の場合)または3個(ベンゼン環の場合)の水素原子が2個のR3基で置換されている場合、R3基は2個でもよく;aが3である場合、すなわちフェニル環上の3個の水素原子が3個のR3 基で置換されている場合、R3基は3個でもよい。
Yが、OまたはSであり;
Cxが、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換4~15員複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、および-CONR6R7、-SO2NR6R7、-SO2R6、-OCOO-R6、-COOR6、-NR6COR7、-OCOR6、-NR6SO2R7、-NR6SO2NR6R7、-COR6、-NR6CONR6R7置換C6-C10アリール、4~15員複素環ラジカル、5~15員ヘテロアリール、および7~15員縮合環からなる群より選択され;R6およびR7はNと共に4~8員Z-置換複素環を形成するか形成せず;
Lが、-O-、-S-、-OCOO-、-NR6CO-、-OCO-、-NR6SO2-、-OCONR6-、四級アンモニウム、およびスルホン酸基-OSO2からなる基から選択され;
Cyが、水素、重水素、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、およびC3-C8シクロアルキルまたはZ-置換C3-C8シクロアルキルからなる群から選択され;または
Cyが、
Cyが、2つのOR6と
-L-Cyが、H原子を失った後にこれらのホスホロアミド酸アルキル化剤の残基を除外し:(-P(Z1)(NR9CH2CH2X1)2、-P(Z1)(NR9 2)(N(CH2CH2X1)2)、-P(Z1)(N(CH2CH2X1))2または-P(Z1)(N(CH2CH2X1)2)2、ここでR9は、各々独立して水素またはC1-C6アルキル、または2つのR9は、それらが結合している窒素原子と共に、5~7員ヘテロシクリルを形成し、Z1はOまたはSであり、X1はCl、BrまたはOMであり、-L-Cyは-OHまたは-SHを除外し;
置換基Zが、ハロゲン原子、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C3アルキルまたは置換アルキル、C1-C3アルコキシまたは置換アルコキシ、C2-C3アルケニルまたは置換アルケニル、C2-C3アルキニルまたは置換アルキニル、C3-C8シクロアルキルまたは置換シクロアルキル、芳香環、複素環、芳香族複素環および縮合環、または、置換芳香環、複素環、または芳香族複素環および縮合環であり、置換のパターンは単一置換-またはジェミナル二置換であり;
Cz基が、対応するC-N、P-NまたはS-N結合が切断されるように加水分解酵素によって加水分解され得るC-、P-、S-含有基である化合物および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物。
式中、
R1およびR2が、それぞれ独立して、水素、重水素、アリールまたはZ-置換アリール、ヘテロアリールまたはZ-置換ヘテロアリール、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、またはC3-C8シクロアルキルまたはZ-置換シクロアルキルであり;
R3が、水素、ハロゲン、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR3が、-CONR6R7、-SO2NR6R7、-SO2R6、-OCO-R6、-OCOO-R6、-COOR6、-NR6COR7、-NR6SO2R7、または-NR6CONR6R7であって、R6およびR7はNと共に、4~8員Z-置換複素環を形成するか形成せず;
R4およびR5が、それぞれ独立して水素、ハロゲン、シアノまたはイソシアノ、ヒドロキシ、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR4およびR5が、それぞれ-CONR6R7、-SO2NR6R7、-SO2R6、-OCOO-R6、-COOR6、-NR6COR7、-OCO-R6、-NR6SO2R7、または-NR6CONR6R7であり、またはR4およびR5は、それが結合しているベンゼン環上の原子と共に、7~15員縮合環またはZ-置換縮合環を形成し、R6およびR7はNと共に、4~8員Z-置換複素環を形成するか形成せず;
R6およびR7が、それぞれ独立して、水素、シアノまたはイソシアノ、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR6およびR7は、それらが結合している原子と共に、3~7員複素環ラジカルまたはZ-置換3~7員複素環ラジカルを形成し、R6およびR7はNと共に、4~8員Z-置換複素環を形成するか形成せず;
Yが、OまたはSであり;
Cxが、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換4~15員複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、および-CONR6R7、-SO2NR6R7、-SO2R6、-OCOO-R6、-COOR6、-NR6COR7、-OCOR6、-NR6SO2R7、-NR6SO2NR6R7、-COR6、-NR6CONR6R7置換C6-C10アリール、4~15員複素環ラジカル、5~15員複素環ラジカル、および7~15員縮合環からなる群より選択され、およびR6およびR7は、Nと共に4~8員Z-置換複素環を形成するか形成せず;
Lが、-O-、-S-、-OCOO-、-NR6CO-、-OCO-、-NR6SO2-、-OCONR6-、四級アンモニウム、およびスルホン酸基-OSO2からなる基から選択され;
Cyが、水素、重水素、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、およびC3-C8シクロアルキルまたはZ-置換C3-C8シクロアルキルからなる群から選択され;または
Cyが、
Cyが、2つのOR6と
上記のH-L-Cyはリン酸アルキル化剤を形成せず;
置換基Zが、ハロゲン原子、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C3アルキルまたは置換アルキル、C1-C3アルコキシまたは置換アルコキシ、C2-C3アルケニルまたは置換アルケニル、C2-C3アルキニルまたは置換アルキニル、C3-C8シクロアルキルまたは置換シクロアルキル、芳香環、複素環、芳香族複素環および縮合環または置換芳香環、複素環、または芳香族複素環および縮合環であり、置換のパターンは単一置換-またはジェミナル二置換であり;
Cz基が、対応するC-N、P-NまたはS-N結合が切断されるように加水分解酵素によって加水分解され得るC-、P-、S-含有基である、つまり、Czがアミノ酸残基(-NH-Czはアミノ酸ペプチド結合を形成する)、有機カルボン酸残基(-NH-Czはアミド構造を形成する)などである化合物または薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物。
EC3.1:エステル結合(エステラーゼ)
EC3.2:糖(グリコシラーゼ)
EC3.3:エーテル結合
EC3.4:ペプチド結合(ペプチダーゼ)
EC3.5:C-N結合(ペプチド結合を除く)
EC3.6:無水物
EC3.7:C-C結合
EC3.8:ハロゲン結合
EC3.9:P-N結合
EC3.10:S-N結合
EC3.11:S-P結合
EC3.12:S-S結合
EC3.13:C-S結合
4員環としては、アゼチジン、オキサエチジン、チアエチジン、およびエチジンが挙げられ;
5員環としては、ピロリジン、ピロリン、1-ピロリン、3-ピロリン、2-ピロリン、ピロ-ル、ピラゾリジン、2-ピラゾリン、イミダゾール、ピラゾール、フラン、テトラヒドロフラン、ジヒドロフラン、テトラヒドロチオフェン、チオフェン、スルホラン、ホスフォール、オキサゾール、1,2,3-トリアゾール、1,2,4-トリアゾール、および1,3,4-チアジアゾールが挙げられ;
6員環としては、ピペリジン、テトラヒドロピラン、テトラヒドロチオピラン、ピリジン、ピラン、チオピラン、ジヒドロピリジン、モルホリン、ピペラジン、ピリダジン、ピラジン、1,3,5-トリアジン、および1,3,5-トリチアンが挙げられ;
7員環としては、アゼパン(アザシクロヘプタン)、オキサヘプタン、チアヘプタン、アゼピン、オキセピン、およびチエピンが挙げられる。
アルド-ケトレダクターゼファミリ-1メンバ-C3(AKR1C3、5型17-β-ヒドロキシステロイドデヒドロゲナーゼ(17-β-HSD5)としても知られる)は、酵素のアルド-ケトレダクターゼ(AKR)スーパーファミリーの一員であり、それはステロイドホルモン中のアルデヒド/ケト基を対応するアルコールに還元するめ、アンドロゲン、プロゲステロン、エストロゲンおよびプロスタグランジンの代謝/活性化/失活に重要な役割を果たす。
(Huhtinen K, Desai R, Stahlee M, et al. Endometrial and Endometriotic Concentrations of Estrone and Estradiol Are Determined by Local Metabolism Rather than Circulating Levels[J]. The Journal of Clinical Endocrinology & Metabolism, 2012, 97(11):4228-4235.DOI: 10.1210/jc.2012-1154)。従って、子宮内膜症病変における局所E2産生の阻害は、子宮内膜症の治療のための非常に魅力的な作用機序と見なされている。AKR1C3は子宮内膜病変で大量に発現し、卵巣ではわずかにしか検出できない。(Tina Smuc, Hevir N, Martina RibicPucelj, et al. Disturbed estrogen and progesterone action in ovarian endometriosis[J]. Molecular & Cellular Endocrinology, 2009, 301(1):59-64.DOI: 10.1016/j.mce.2008.07.020)。CYP19A1(アロマターゼ)との相乗作用において、AKR1C3は子宮内膜症病変における局所E2産生の重要な酵素であり、それによりエストロゲン促進環境を生じ、エストロゲン感受性子宮内膜症細胞の増殖を刺激することが期待される。したがって、AKR1C3の阻害は局所的な組織内E2レベルの低下をもたらし、それによって子宮内膜症病変の増殖を減少させるはずである。卵巣ではAKR1C3がごくわずかにしか発現しておらず、17βHSD1が優位な卵巣ヒドロキシステロイド脱水素酵素であることから、卵巣のエストロゲン産生に対する効果は期待できない。
AKR1C3をコードするAKR1C3遺伝子における遺伝子多型もまた、前立腺癌の独立した予測因子であることが示された(Yu et.al, PLoS One 2013, 8(1):e54627.DOI: 10.1371/journal.pone.0054627)。さらに、AKR1C3依存性アンドロゲンデノボ合成は、アビラテロンなどのCYP17A1阻害剤に対する耐性の潜在的作用機序であることが示唆された(Mostaghel et.al, Clin Cancer Res 2011, 17:5913-5925.DOI:10.1158/1078-0432.CCR-11-0728; Cai et.al, Cancer Res 2011, 71:6503-6513.DOI:10.1158/0008-5472.CAN-11-0532)。したがって、AKR1C3はCRPC患者における有望な治療標的となる可能性がある(Adeniji et.al, J Steroid Biochem Mol Biol 2013, 137:136-149.DOI:10.1021/jm3017656)。AKR1C3阻害剤は、転移性去勢耐性前立腺癌患者を対象とした多施設共同第I/II相試験において検証された。しかしながら、新規アンドロゲン生合成阻害剤は臨床活性の関連する証拠を示さなかった(Loriot et.al, Invest New Drugs 2014, 32:995-1004.DOI:10.1007/s10637-014-0101-x)。最近の情報は、CRPCにおけるAKR1C3活性化が抗アンドロゲン(エンザルタミド)耐性に関連する重要な耐性作用機序であることを示している。エンザルタミド耐性前立腺癌細胞では、親細胞と比較して、コレステロール、DHEA、およびプロゲステロンなどのアンドロゲン前駆体、ならびにアンドロゲンが高度にアップレギュレートされていることが示された。この情報は、AKR1C3の阻害経路が、エンザルタミド感作治療として作用し、エンザルタミド耐性CRPCの患者に対して回復効果を示す可能性があることを示している。(Liu C, Lou W, Zhu Y, et al. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer[J]. Cancer Research, 2015, 75(7):1413-1422.DOI:10.1158/0008-5472.can-14-3080)。AKR1C3阻害剤との併用治療はエンザルタミドに対する耐性を克服し、進行性前立腺癌患者の生存率を改善すると想定される(Thoma et.al, Nature Reviews Urology 2015, 12:124.DOI:10.1038/nrurol.2015.23)。
線形加速器によって多数の光子(γ線)ビームが放出される、光子(γ線)ビーム放出;
狭い組織縁を有する一定の癌腫を治療するために使用できる、中性子線照射;
浸透組織の深さが非常に浅いため、皮膚または表在性癌腫の治療に有用な、電子線照射;
使用に限界があるが、特定の深さを必要とする非常に狭い照射野に対して鋭い光線を提供する、陽子放射線;
強力な放射線源を針を通して腫瘍組織自体(例えば、前立腺または肺)に埋め込み、狭い範囲および高い線量で効果を発揮する、小線源療法;
核種を取り込む臓器受容体(甲状腺癌など)または全身の骨格部位を阻害する受容体(転移性前立腺癌を治療するための放射性ストロンチウムなど)に使用できる、全身性放射性核種療法;
一般に、腫瘍を局所的に、またはその局所領域を照射野内に含める、根治的放射線療法;
が、最も一般的に使用される。
合成方法の概要
MTBEはメチルtert-ブチルエーテル、DMAPは4-ジメチルアミノピリジン、T3Pはプロピルホスホン酸無水物、THFはテトラヒドロフラン、DCMはジクロロメタン、EAまたはEtOACは酢酸エチル、TEAはトリエチルアミン、HPLCは高速液体クロマトグラフィー、DBADはジ-tert-ブチルアゾジカルボン酸、TFAはトリフルオロ酢酸、LCMSは液体クロマトグラフィー質量分析、EtOHはエタノール、t-BuOHはtert-ブタノール、DMFはジメチルホルムアミド、PEは石油エーテル、eq.は当量、すなわちモル比、TBAFはフッ化テトラブチルアンモニウム、DIPEAはN,N-ジイソプロピルエチルアミン、refluxは逆流、rtは室温を表す。
化合物#1を、上記化合物#2/3と同様の方法で合成した。
実験装置:
四重極飛行時間型質量分析計(Xevo G2-XS QTof)搭載の超高性能液体クロマトグラフACQUITY UPLC I-Class PLUS(Waters社)
1.PBSリン酸緩衝食塩水
2.20mMのNADPHを含むPBSリン酸緩衝生理食塩液
3.250μg/mLのAKR1C3を含むPBSリン酸緩衝生理食塩液
4.250μΜの試験化合物を含む50%のMeOH/H2O
5.250μΜのプロゲステロンを含む50%のMeOH/H2O
6.1μg/mLのプロプラノロールを含む100%アセトニトリル
工程1において、反応混合物を、以下の表にしたがって2回(n=2)エッペンドルフチューブ中に調製し、穏やかに混合した。
Claims (29)
- 下記式の化合物および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物:
R1およびR2が、それぞれ独立して、水素、重水素、アリールまたはZ-置換アリール、ヘテロアリールまたはZ-置換ヘテロアリール、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、またはC3-C8シクロアルキルまたはZ-置換シクロアルキルであり;
R3が水素、ハロゲン、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR3が-CONR6R7、-SO2NR6R7、-SO2R6、-OCO-R6、-OCOO-R6、-COOR6、-NR6COR7、-NR6SO2R7、または-NR6CONR6R7であり、R6およびR7はNと共に、4~8員Z-置換複素環を形成するか形成せず、または2つのR3は、それが結合しているベンゼン環上の原子と共に、7~15員縮合環またはZ-置換縮合環を形成し;
R6およびR7が、それぞれ独立して、水素、シアノまたはイソシアノ、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシ、またはR6およびR7は、それらが結合している原子と共に、3~7員複素環ラジカルまたはZ-置換3~7員複素環ラジカルを形成し;
aが、0、1、2または3であり;
Xが、CまたはNであり;
Yが、OまたはSであり;
Cxが、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換4~15員複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、および-CONR6R7、-SO2NR6R7、-SO2R6、-OCOO-R6、-COOR6、-NR6COR7、-OCOR6、-NR6SO2R7、-NR6SO2NR6R7、-COR6、-NR6CONR6R7置換C6-C10アリール、4~15員複素環ラジカル、5~15員ヘテロアリール、および7~15員縮合環からなる群より選択され;R6およびR7は、Nと共に4~8員Z-置換複素環を形成するか形成せず;
Lが、-O-、-S-、-OCOO-、-NR6CO-、-OCO-、-NR6SO2-、-OCONR6-、四級アンモニウム、およびスルホン酸基-OSO2からなる基から選択され;
Cyが、水素、重水素、C6-C10アリールまたはZ-置換アリール、4~15員複素環またはZ-置換複素環、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、およびC3-C8シクロアルキルまたはZ-置換C3-C8シクロアルキルからなる群から選択され;または
Cyが、
Cyが、2つのOR6と
-L-Cyが、H原子を失った後にこれらのホスホロアミド酸アルキル化剤の残基を除外し:-P(Z1)(NR9CH2CH2X1)2、-P(Z1)(NR9 2)(N(CH2CH2X1)2)、-P(Z1)(N(CH2CH2X1))2または-P(Z1)(N(CH2CH2X1)2)2、ここでR9は、各々独立して水素またはC1-C6アルキル、または2つのR9は、それらが結合している窒素原子と共に、5~7員ヘテロシクリルを形成し、Z1は、OまたはSであり、X1は、Cl、BrまたはOMであり、-L-Cyは-OHまたは-SHを除外し;
置換基Zが、ハロゲン原子、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C3アルキルまたは置換アルキル、C1-C3アルコキシまたは置換アルコキシ、C2-C3アルケニルまたは置換アルケニル、C2-C3アルキニルまたは置換アルキニル、C3-C8シクロアルキルまたは置換シクロアルキル、芳香環、複素環、芳香族複素環および縮合環、または、置換芳香環、複素環、または芳香族複素環および縮合環であり、置換のパターンは単一置換-またはジェミナル二置換であり;
Cz基が、対応するC-N、P-NまたはS-N結合が切断されるように加水分解酵素によって加水分解され得るC-、P-、S-含有基である化合物および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物。 - 前記化合物が式I:
式中、
I-5が、in vivoで上記化合物I-3に変換できるプロドラッグであり、
R1およびR2が、それぞれ独立して、水素、重水素、アリールまたはZ-置換アリール、ヘテロアリールまたはZ-置換ヘテロアリール、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、またはC3-C8シクロアルキルまたはZ-置換シクロアルキルであり;
R3が、水素、ハロゲン、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR3が、-CONR6R7、-SO2NR6R7、-SO2R6、-OCO-R6、-OCOO-R6、-COOR6、-NR6COR7、-NR6SO2R7、または-NR6CONR6R7であって、R6およびR7は、Nと共に、4~8員Z-置換複素環を形成するか形成せず;
R4およびR5が、それぞれ独立して水素、ハロゲン、シアノまたはイソシアノ、ヒドロキシ、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR4およびR5が、それぞれ-CONR6R7、-SO2NR6R7、-SO2R6、-OCOO-R6、-COOR6、-NR6COR7、-OCO-R6、-NR6SO2R7、または-NR6CONR6R7であり、またはR4およびR5は、それが結合しているベンゼン環上の原子と共に、7~15員縮合環またはZ-置換縮合環を形成し、R6およびR7は、Nと共に、4~8員Z-置換複素環を形成するか形成せず;
R6およびR7が、それぞれ独立して、水素、シアノまたはイソシアノ、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、C3-C8シクロアルキルまたはZ-置換シクロアルキル、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、またはC1-C6アルコキシまたはZ-置換C1-C6アルコキシであり;またはR6およびR7は、それらが結合している原子と共に、3~7員ヘテロシクリルまたはZ-置換3~7員ヘテロシクリルを形成し、R6およびR7は、Nと共に、4~8員Z-置換複素環を形成するか形成せず;
Yが、OまたはSであり;
Cxが、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換4~15員複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、および-CONR6R7、-SO2NR6R7、-SO2R6、-OCOO-R6、-COOR6、-NR6COR7、-OCOR6、-NR6SO2R7、-NR6SO2NR6R7、-COR6、-NR6CONR6R7置換C6-C10アリール、4~15員複素環ラジカル、5~15員ヘテロアリール、および7~15員縮合環からなる群より選択され、R6およびR7は、Nと共に、4~8員Z-置換複素環を形成するか形成しない7;
Lが、-O-、-S-、-OCOO-、-NR6CO-、-OCO-、-NR6SO2-、-OCONR6-、四級アンモニウム、およびスルホン酸基-OSO2からなる基から選択され;
Cyが、水素、重水素、C6-C10アリールまたはZ-置換アリール、4~15員複素環ラジカルまたはZ-置換複素環ラジカル、5~15員ヘテロアリールまたはZ-置換ヘテロアリール、7~15員縮合環またはZ-置換縮合環、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、およびC3-C8シクロアルキルまたはZ-置換C3-C8シクロアルキルからなる群から選択され;または
Cyが、
Cyが、2つのOR6と
置換基Zが、ハロゲン原子、シアノまたはイソシアノ、ヒドロキシル、メルカプト、アミノ、オキシミド、ヒドラゾノ、OT、OM、C1-C3アルキルまたは置換アルキル、C1-C3アルコキシまたは置換アルコキシ、C2-C3アルケニルまたは置換アルケニル、C2-C3アルキニルまたは置換アルキニル、C3-C8シクロアルキルまたは置換シクロアルキル、芳香環、複素環、芳香族複素環および縮合環、または、置換芳香環、複素環、または芳香族複素環および縮合環であり、置換のパターンは単一置換-またはジェミナル二置換であり;
Cz基が、対応するC-N、P-NまたはS-N結合が切断されるように加水分解酵素によって加水分解され得るC-、P-、S-含有基である、請求項1に記載の化合物。 - R1およびR2が、それぞれ独立して、水素、重水素、C1-C6アルキルまたはZ-置換アルキル、C2-C6アルケニルまたはZ-置換アルケニル、C2-C6アルキニルまたはZ-置換アルキニル、またはC3-C8シクロアルキルまたはZ-置換シクロアルキルである、請求項1または2に記載の化合物。
- R1およびR2が、それぞれ独立して、水素、重水素、またはメチルである、請求項3に記載の化合物。
- R3、R4およびR5が、それぞれ独立して、水素である、請求項1~4のいずれか一項に記載の化合物。
- Cxが、-CONR6R7置換フェニルであり、R6およびR7は、Nと共に、4~8員Z-置換複素環を形成するか形成しない、請求項1~5のいずれか一項に記載の化合物。
- Lが、-O-または-S-から選択される、請求項1~6のいずれか一項に記載の化合物。
- Cyが、C6-C10アリールまたはハロ置換アリール、4~15員複素環またはハロ置換複素環、5~15員ヘテロアリールまたはハロ置換ヘテロアリール、および7~15員縮合環またはハロ置換縮合環からなる群より選択される、請求項1~7のいずれか一項に記載の化合物。
- Cyが、フルオロフェニル、ジフルオロフェニル、およびトリフルオロフェニルからなる群から選択される、請求項8のいずれか一項に記載の化合物。
- Czが、-COR6または-COOR6から選択される、請求項1または2に記載の化合物。
- -NH-Czが、ホスファミド基である、請求項1~10のいずれか一項に記載の化合物。
- 前記塩が、塩基性塩または酸性塩であり、前記溶媒和物が水和物またはアルコラートである、請求項1~13のいずれか一項に記載の化合物。
- 請求項1~13のいずれか一項に記載の化合物と、薬学的に許容される塩、またはその溶媒和物、または同位体置換化合物とを含む、医薬。
- 子宮内膜症、子宮平滑筋腫、子宮出血性疾患、月経困難症、前立腺肥大症、ざ瘡、脂漏症、脱毛症、性的早熟、多のう胞性卵巣症候群、慢性閉塞性肺疾病COPD、肥満、炎症性疼痛、癌、炎症、または癌性疼痛を含む疾患/状態を予防または治療するために使用される、請求項15に記載の医薬。
- 癌が、前立腺癌、原発性前立腺癌、進行性前立腺癌、転移性前立腺癌、ホルモン未投与前立腺癌、難治性前立腺癌、去勢耐性前立腺癌CRPC、乳癌、肺癌、子宮内膜癌、腎細胞癌、膀胱癌、非ホジキンリンパ腫、急性骨髄性白血病AML、T細胞急性リンパ芽球性白血病T-ALL、および白血病を含む、請求項16記載の医薬。
- 子宮内膜症、子宮平滑筋腫、子宮出血性疾患、月経困難症、前立腺肥大症、ざ瘡、脂漏症、脱毛症、性的早熟、多のう胞性卵巣症候群、慢性閉塞性肺疾病COPD、肥満、炎症性疼痛、癌、炎症、または癌性疼痛を含む、関連疾患/障害を治療または予防するための医薬の製造における、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、またはその溶媒和物、または同位体置換化合物の使用。
- 請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物を含み、
癌または腫瘍のある患者が放射線療法に耐性がある場合に放射線療法の有効性を高めるため、または放射線療法に耐性のある癌または腫瘍のある患者を治療するために使用される癌や腫瘍の放射線療法に対する感受性を高めるための医薬。 - 請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物を含み、
癌または腫瘍のある患者が免疫療法に耐性がある場合に放射線療法の有効性を高めるため、または免疫療法に耐性のある癌または腫瘍のある患者を治療するために使用される癌や腫瘍の免疫療法に対する感受性を高めるための医薬。 - 請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物を含み、
癌または腫瘍のある患者が化学療法に耐性がある場合に化学線療法の有効性を高めるため、または化学療法に耐性のある癌または腫瘍のある患者を治療するために使用される癌や腫瘍の化学療法に対する感受性を高めるための医薬。 - 請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物を含み、
癌または腫瘍のある患者が化学療法に耐性がある場合に化学線療法の有効性を高めるため、または化学療法に耐性のある癌または腫瘍のある患者を治療するために使用され、ダウノールビシンまたはシタラビンを含有する癌や腫瘍の化学療法に対する感受性を高めるための医薬。 - ダウノールビシンまたはシタラビンを含有する医薬を使用する、癌または腫瘍の放射線療法に対する感受性を高めるため、または癌または腫瘍の化学療法に対する感受性を高めるための、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、またはその同位体置換化合物の使用。
- AKR1C3酵素阻害剤としての、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、またはその溶媒和物、または同位体置換化合物の使用。
- AKR1C3酵素阻害剤である医薬の製造における、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、または同位体置換化合物の使用。
- 癌または腫瘍のある患者が放射線療法に耐性がある場合に放射線療法の有効性を高めるため、または放射線療法に耐性のある癌または腫瘍のある患者を治療するために使用される医薬の製造における、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、または同位体置換化合物の使用。
- 癌または腫瘍のある患者が免疫療法に耐性がある場合に放射線療法の有効性を高めるため、または免疫療法に耐性のある癌または腫瘍のある患者を治療するために使用される医薬の製造における、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、または同位体置換化合物の使用。
- 癌または腫瘍のある患者が化学療法に耐性がある場合に化学療法の有効性を高めるため、または化学療法に耐性のある癌または腫瘍のある患者を治療するために使用される医薬の製造における、請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、または同位体置換化合物の使用。
- 癌または腫瘍のある患者が化学療法に耐性がある場合に化学療法の有効性を高めるため、または化学療法に耐性のある癌または腫瘍のある患者を治療するために使用され、ダウノールビシンまたはシタラビンを含有する医薬の製造における請求項1~13のいずれか一項に記載の化合物、および薬学的に許容される塩、または溶媒和物、または同位体置換化合物の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910585317.9 | 2019-07-01 | ||
CN201910585317.9A CN112174865A (zh) | 2019-07-01 | 2019-07-01 | Akr1c3抑制剂及医药用途 |
CN201911323885 | 2019-12-20 | ||
CN201911323885.8 | 2019-12-20 | ||
PCT/CN2020/099353 WO2021000862A1 (zh) | 2019-07-01 | 2020-06-30 | Akr1c3抑制剂及医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022538602A true JP2022538602A (ja) | 2022-09-05 |
Family
ID=73475312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021577319A Pending JP2022538602A (ja) | 2019-07-01 | 2020-06-30 | Akr1c3阻害剤およびその医学的使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220251021A1 (ja) |
EP (1) | EP3995480A4 (ja) |
JP (1) | JP2022538602A (ja) |
KR (1) | KR20220030256A (ja) |
CN (2) | CN116554071A (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024051792A1 (zh) * | 2022-09-09 | 2024-03-14 | 深圳艾欣达伟医药科技有限公司 | Ast-3424联用治疗白血病及淋巴瘤 |
WO2024155618A1 (en) * | 2023-01-16 | 2024-07-25 | Case Western Reserve University | Compositions and methods for treating weight gain and/or disorders associated with abnormal de novo lipogenesis, and fat accumulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214798A1 (en) * | 2003-04-22 | 2004-10-28 | Longqin Hu | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation |
CN102924507A (zh) * | 2011-11-10 | 2013-02-13 | 安徽四维药业有限公司 | 一种抗肿瘤化合物及其制备方法与应用、药物组合物 |
WO2017087428A1 (en) * | 2015-11-16 | 2017-05-26 | Threshold Pharmaceuticals, Inc. | (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation |
ES2828026T3 (es) * | 2015-03-10 | 2021-05-25 | Obi Pharma Inc | Agentes alquilantes del ADN |
JP6612892B2 (ja) * | 2015-04-02 | 2019-11-27 | アセンタウィッツ ファーマシューティカルズ リミテッド | 抗がん剤のニトロベンジル誘導体 |
TW201919644A (zh) * | 2017-09-29 | 2019-06-01 | 台灣浩鼎生技股份有限公司 | 治療血癌的方法 |
CN109897085A (zh) * | 2017-12-11 | 2019-06-18 | 上海健康医学院 | 一种雷公藤衍生物及应用 |
EP3971194A4 (en) * | 2019-05-13 | 2023-05-31 | Ascentawits Pharmaceuticals, Ltd. | FLUORINE CONTAINING COMPOUND AND ITS MEDICAL USE ANTI-CANCER |
-
2020
- 2020-06-30 US US17/623,666 patent/US20220251021A1/en active Pending
- 2020-06-30 KR KR1020227002569A patent/KR20220030256A/ko unknown
- 2020-06-30 JP JP2021577319A patent/JP2022538602A/ja active Pending
- 2020-06-30 CN CN202310332716.0A patent/CN116554071A/zh active Pending
- 2020-06-30 CN CN202080001496.8A patent/CN112004799B/zh active Active
- 2020-06-30 EP EP20834153.7A patent/EP3995480A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116554071A (zh) | 2023-08-08 |
KR20220030256A (ko) | 2022-03-10 |
CN112004799A (zh) | 2020-11-27 |
EP3995480A4 (en) | 2023-10-25 |
CN112004799B (zh) | 2023-05-02 |
EP3995480A1 (en) | 2022-05-11 |
US20220251021A1 (en) | 2022-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021129820A1 (zh) | 含螺环的喹唑啉化合物 | |
CN102686600A (zh) | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 | |
JP2022538602A (ja) | Akr1c3阻害剤およびその医学的使用 | |
PT1778710E (pt) | Derivados de tanaproget, metabolitos e suas utilizações | |
US20230134986A1 (en) | Glucose triptolide conjugates and uses thereof | |
KR20150118153A (ko) | 17.베타.-히드록시스테로이드 데히드로게나제 (akr1 c3)의 억제를 위한 에스트라-1,3,5(10),16-테트라엔-3-카르복스아미드 | |
EP2688901B1 (en) | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 | |
BR112013005843A2 (pt) | derivativos de er-beta 6-substituído por desmetil-estradiol | |
US8680251B2 (en) | Triterpenoid 2-deoxy glycosides, method of preparation thereof and use thereof as medicaments | |
AU2016229991A1 (en) | Altering steroid metabolism for treatment of steroid-dependent disease | |
US7732493B2 (en) | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | |
EP3237430B1 (en) | PRODRUGS OF 17ß -HSD1 -INHIBITORS | |
CN112174865A (zh) | Akr1c3抑制剂及医药用途 | |
Dupommier et al. | New desulfured troglitazone derivatives: Improved synthesis and biological evaluation | |
EP4389756A1 (en) | Abiraterone derivative and preparation and application thereof | |
WO2023025241A1 (zh) | 一种阿比特龙前体化合物及其制备方法和应用 | |
Liu et al. | Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs | |
WO2021000862A1 (zh) | Akr1c3抑制剂及医药用途 | |
TW202136201A (zh) | Akr1c3抑制劑及醫藥用途 | |
EP3805243B1 (en) | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure | |
US8969327B2 (en) | Substituted androst-4-ene diones | |
BRPI0721050A2 (pt) | Derivados de 6-alquoxialquil estradiol e métodos de uso | |
Yeşilağaç et al. | Enzymatic synthesis of 125/131I labeled 8-hydroxyquinoline glucuronide and in vitro/in vivo evaluation of biological influence | |
US20040180841A1 (en) | Apoptolidin analogs and derivatives for inducing apoptosis in transformed cells | |
WO2019056375A1 (zh) | 酸敏感的吉非替尼轴向取代酞菁硅配合物及其制备方法和在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230119 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240625 |